Molecular Templates (MTEM) Competitors

Amgen (NASDAQ:AMGN) and Molecular Templates (NASDAQ:MTEM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Does the media refer more to AMGN or MTEM?

In the previous week, Amgen had 61 more articles in the media than Molecular Templates. MarketBeat recorded 61 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.53 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the media.

Company	Overall Sentiment
Amgen	Very Positive
Molecular Templates	Neutral

Which has better valuation and earnings, AMGN or MTEM?

Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.87	$4.09B	$7.55	40.13
Molecular Templates	$57.31M	0.00	-$8.12M	-$2.70	0.00

Which has more volatility & risk, AMGN or MTEM?

Amgen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Do institutionals and insiders believe in AMGN or MTEM?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 95.5% of Molecular Templates shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 13.9% of Molecular Templates shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate AMGN or MTEM?

Amgen currently has a consensus target price of $314.09, suggesting a potential upside of 3.66%. Given Amgen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Amgen is more favorable than Molecular Templates.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	10 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.46
Molecular Templates	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is AMGN or MTEM more profitable?

Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Molecular Templates	-61.35%	-260.50%	-46.90%

Does the MarketBeat Community favor AMGN or MTEM?

Amgen received 1208 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 72.03% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1550 72.03%	Underperform Votes 602 27.97%
Molecular Templates	Outperform Votes 342 67.32%	Underperform Votes 166 32.68%

Summary

Amgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks.